Slides
Page 1
ANNUAL SHAREHOLDER MEETING 2026
Page 2
ATTENDEES QUESTION & VOTING PROCESS
Page 3
MEETING AGENDA B US I N E SS OF T H E ME E TI N G CHAIR'S ADDRESS Dame Alison Stewart CHIEF EXECUTIVE OFFICER'S ADDRESS Scott Johnson RESOLUTIONS 1. That Paul Munro be elected as a Director 2. That pursuant to NZX Listing Rule 2.11.1, the maximum aggregate amount of remuneration payable by the Company to Directors be increased from $309,000 per annum to $340,000 per annum 3. That the Directors be authorised to fix the remuneration of the auditors for the ensuing year OTHER BUSINESS
Page 4
BOARD OF DIRECTORS DAME ALISON STEWART Chair, Independent Non- executive Director Member of People & Performance Committee AMELIA (AIMEE) MCCAMMON Independent Non- executive Director Chair of People & Performance Committee; Member of Audit & Risk Committee DR BARRY RICHARDSON Independent Non- executive Director Member of Audit & Risk Committee; Member of People & Performance Committee PAUL MUNRO Independent Non- executive Director Chair of Audit & Risk Committee ANITA JOHANSEN Non-executive Director
Page 5
FY26 SUMMARY $ 14.7M REVENUE ▲ 16% on prior year $ 1.8M UNDERLYING EBITDA* ▲ 83% on prior year $ 1.6M UNDERLYING NPAT* ▲ 90% on prior year $ 8.5M CASH & DEPOSITS At 31 March 2026
Page 6
CEO ADDRESS SCOTT JOHNSON Chief Executive Officer
Page 7
EXECUTIVE TEAM SCOTT JOHNSON Chief Executive Officer (CEO) RICHARD WINGHAM Chief Financial Officer (CFO) JENNIFER WALKER Chief Revenue Officer (CRO) DR JOHN HALE Chief Technology Officer (CTO) ASHLEIGH CHILDS Head of People, Culture & PMO MELISSA DRYSDALE Head of Quality
Page 8
GLOBAL MARKET SNAPSHOT PROBIOTIC DIETARY SUPPLEMENT MARKET Market size in USD Billion · CAGR 11.74% $12.52B 2025 $13.98B 2026 $24.35B 2031 Source: Mordor Intelligence GLOBAL PROBIOTIC DIETARY SUPPLEMENTS MARKET BY REGION (2024) 22% Europe 25% North America 37.8% Asia-Pacific 5.4% Rest of World 10% Middle East & Africa Source: Mordor Intelligence, 2025
Page 9
FY26 FINANCIAL PERFORMANCE REVENUE ▲ 16% on prior year $m 11.5 FY24 12.6 FY25 14.7 FY26 UNDERLYING EBITDA* ▲ 83% on prior year $m 0.8 FY24 1.0 FY25 1.8 FY26 UNDERLYING NPAT* ▲ 90% on prior year $m 0.6 FY24 0.8 FY25 1.6 FY26 * Underlying EBITDA and NPAT adjust for a $0.9m one-off supply chain cost increase during FY26.
Page 10
FY26 SUMMARY REVENUE BY REGION FY26FY25 EMEA New Zealand Asia Pacific (excl. NZ) North America REVENUE BY CHANNEL FY26 FY25 B2B B2C CASH GENERATED FROM OPERATIONS ▼ 133% on prior year $m 1.1 1.8 (0.6) FY24 FY25 FY26 FY26 reflects investment in inventory during the period. 20 Publications relating to our strains 17 Conferences attended or presented at 2 New patents granted Progression of China regulatory project to examination stage
Page 11
REVENUE & MARKET PERFORMANCE - B2B $ 9.9M B2B REVENUE ▲ 22% • Ingredient $7.3m, up 17% - the primary growth driver. • Asia Pacific up $0.9m - new South Korea customer • Royalty $1.3m, up 17% • Private label $1.3m, up 67% - China offline expansion B2B REVENUE (NZ$M) 8.0 FY24 8.1 FY25 9.9 FY26 FY26 B2B REVENUE BY SALES CHANNEL Ingredient Royalty Private label
Page 12
REVENUE & MARKET PERFORMANCE - B2C $ 4.8M B2C REVENUE • New Zealand Wholesale – up 20% - strong product ranging and growing focus on dental • Amazon US up 5%, despite tariffs • BLIS Webstore up 12% • CBEC $0.3m, down from $0.6m in FY25 - pricing reset to align with new China partners and managed exit of smaller diagou resellers from market B2C REVENUE (NZ$M) 3.5 FY24 4.5 FY25 4.8 FY26 FY26 B2C REVENUE BY CHANNEL NZ Wholesale Amazon BLIS Webstore China CBEC
Page 13
INTELLECTUAL PROPERTY & MARKET RISKS IP MATTER RESOLVED • Patent issue with Bluestone Pharma (BSP) & Lactosan GmbH resolved in July 2025 • Relevant patents now jointly owned by BLIS & BSP; all claims released • Five-year extension to the BSP supply agreement secured NEW PATENTS GRANTED • Antiviral applications of Streptococcus salivarius K12 and M18 • Enhanced formulations combining BLIS strains with specific prebiotic sugars CHINA REGULATORY • Key clinical trial, central to China regulatory strategy, commenced in 2HY26 and is expected to be complete in 1HY27. PROBI • Revised Technology License and Distribution Agreement with Probi AB in October 2025 • Introduces pet nutrition into Probi’s licensed territories
Page 14
STRATEGIC FOCUS & EXECUTION CONTINUED FOCUS ON CORE: BLIS K12 & BLIS M18 EXPANDED PROBI AGREEMENT — USA, CANADA, EMEA & PET NUTRITION CHINA CLINICAL TRIAL UNDERWAY — COMPLETION EXPECTED 1H27 CONSUMER-INSIGHT- DRIVEN R&D, NPD AND BRAND REFRESH
Page 15
FY27 STRATEGIC PLAN O U R P U R PO S E Being the best at developing probiotic solutions for the health and wellbeing of global consumers OUR IMPACT PEOPLE PROFIT CUSTOMER OUR VISION We are recognised globally as the preferred partner and leader in oral probiotic innovation HOW WE DELIVER CREATE TECHNOLOGY BLOCKS GROW GLOBAL PARTNERSHIPS BUILD BRAND BLIS RIGHT PEOPLE SECURE SUPPLY QUALITY PROCESSES & SYSTEMS OUR VALUES OUR MANA CUSTOMER FIRST MAKE IT HAPPEN ONE TEAM
Page 16
ESG & CULTURE B CORP CERTIFICATION MYGREEN LAB CERTIFICATION MAINTAINED 'LEADING AT BLIS' LEADERSHIP PROGRAMME 0 LTI’S - 7 YEARS LTI FREE HEALTH & SAFETY EXTERNAL AUDIT COMPLETED
Page 17
SUPPLY CHAIN ONE-OFF COST OF $0.9M IMPACTED FY26 EARNINGS ADDITIONAL FERMENTATION PARTNER
Page 18
CLOSING & OUTLOOK UNAUDITED RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 (1Q27) $5.1M REVENUE $1.1M EBITDA FY27 PRIORITIES • Accelerate growth in key markets with the right partners • Advance R&D, new product development and IP protection • Invest in building the BLIS brand: Masters of the Oral Microbiome • Maintain financial discipline for sustainable, profitable growth FY27 OUTLOOK • FY27 full year revenue growth of 10-15%
Page 19
QUESTIONS W A I T F O R T H E M I C R O P H O N E
Page 20
ATTENDEES QUESTION PROCESS ? QUESTION BOX Select "Ask a Question" in the online portal, type your question, and submit it to the Chair.
Page 21
RESOLUTIONS W A I T F O R T H E M I C R O P H O N E
Page 22
ATTENDEES VOTING PROCESS + VOTING CARD Select "Get a Voting Card" in the online portal, then cast your vote For, Against or Abstain on each resolution.
Page 23
R E SOL UT ION 1 THAT PAUL MUNRO BE ELECTED AS A DIRECTOR OF THE COMPANY WA IT FO R TH E MI CR OP HON E State your name and whether you are a shareholder or proxy holder
Page 24
R E SOL UT ION 2 THAT PURSUANT TO NZX LISTING RULE 2.11.1, THE MAXIMUM AGGREGATE AMOUNT OF REMUNERATION PAYABLE BY THE COMPANY TO DIRECTORS BE INCREASED FROM $309,000 PER ANNUM TO $340,000 PER ANNUM WA IT FO R TH E MI CR OP HON E State your name and whether you are a shareholder or proxy holder
Page 25
R E SOL UT ION 3 THAT THE DIRECTORS BE AUTHORISED TO FIX THE REMUNERATION OF THE AUDITORS FOR THE ENSUING YEAR WA IT FO R TH E MI CR OP HON E State your name and whether you are a shareholder or proxy holder
Page 26
GENERAL BUSINESS
Page 27
DISCLAIMER INFORMATION The information in this presentation is an overview and does not contain all information necessary to make an investment decision. It is intended to constitute a summary of certain information relating to the performance of BLIS Technologies Limited (“Company” or “BLIS”). The information in this presentation is of a general nature and does not purport to be complete. This presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements, which are available at nzx.com. NOT FINANCIAL PRODUCT ADVICE This presentation is for information purposes only and is not financial or investment advice or a recommendation to acquire BLIS securities and has been prepared without taking into account the objectives, financial situation or needs of individuals. The Company, its directors and employees do not give or make any recommendation or opinion in relation to acquiring or disposing of shares. In making an investment decision, investors must rely on their own examination of the Company, including the merits and risks involved. Investors should consult their own legal, tax, business and/or financial advisers in connection with any acquisition of securities. FUTURE PERFORMANCE This presentation may contain certain ‘forward-looking statements’, for example statements concerning the development and commercialisationof new products, regulatory approvals, customer adoption and results of future clinical studies. Forward-looking statements can generally be identified by the use of forward- looking words such as ‘expect’, ‘anticipate’, likely’, ‘intend’, ‘could’, ‘may’, ‘predict’, ‘plan’, ‘propose’, ‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’, ‘guidance’, and other similar expressions. The forward-looking statements contained in this presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, of which are beyond the control of the Company and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. There can be no assurance that actual outcomes will not materially differ from these forward-looking statements. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements. The forward-looking statements are based on information available to the Company as at the date of this presentation. Except as required by law or regulation (including the NZX Main Board Listing Rules), the Company undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. NO REPRESENTATION This presentation may contain information from third parties believed to be reliable; however, no representations or warranties are made as to its accuracy or completeness.
Page 28
THANK YOU P R O B I O T I C S M A D E T O M A T T E R